vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
STURM RUGER & CO INC is the larger business by last-quarter revenue ($151.1M vs $85.1M, roughly 1.8× 4D Molecular Therapeutics, Inc.). On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs 3.6%). 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $12.3M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 5.1%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
FDMT vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $151.1M |
| Net Profit | $19.4M | — |
| Gross Margin | — | 17.8% |
| Operating Margin | 17.3% | 2.3% |
| Net Margin | 22.8% | — |
| Revenue YoY | 8508900.0% | 3.6% |
| Net Profit YoY | 139.1% | — |
| EPS (diluted) | $0.43 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $85.1M | $151.1M | ||
| Q3 25 | $90.0K | $126.8M | ||
| Q2 25 | $15.0K | $132.5M | ||
| Q1 25 | $14.0K | $135.7M | ||
| Q4 24 | $1.0K | $145.8M | ||
| Q3 24 | $3.0K | $122.3M | ||
| Q2 24 | $5.0K | $130.8M | ||
| Q1 24 | $28.0K | $136.8M |
| Q4 25 | $19.4M | — | ||
| Q3 25 | $-56.9M | $1.6M | ||
| Q2 25 | $-54.7M | $-17.2M | ||
| Q1 25 | $-48.0M | $7.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-43.8M | $4.7M | ||
| Q2 24 | $-35.0M | $8.3M | ||
| Q1 24 | $-32.4M | $7.1M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | 17.3% | 2.3% | ||
| Q3 25 | -67983.3% | -2.7% | ||
| Q2 25 | -396373.3% | -15.6% | ||
| Q1 25 | -383007.1% | 6.2% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | -1704400.0% | 3.1% | ||
| Q2 24 | -849120.0% | 6.9% | ||
| Q1 24 | -136200.0% | 5.5% |
| Q4 25 | 22.8% | — | ||
| Q3 25 | -63195.6% | 1.2% | ||
| Q2 25 | -364386.7% | -13.0% | ||
| Q1 25 | -342657.1% | 5.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -1461433.3% | 3.9% | ||
| Q2 24 | -699060.0% | 6.3% | ||
| Q1 24 | -115717.9% | 5.2% |
| Q4 25 | $0.43 | $0.22 | ||
| Q3 25 | $-1.01 | $0.10 | ||
| Q2 25 | $-0.98 | $-1.05 | ||
| Q1 25 | $-0.86 | $0.46 | ||
| Q4 24 | — | $0.62 | ||
| Q3 24 | $-0.79 | $0.28 | ||
| Q2 24 | $-0.63 | $0.47 | ||
| Q1 24 | $-0.66 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $92.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $283.8M |
| Total Assets | $566.7M | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $402.7M | $92.5M | ||
| Q3 25 | $305.1M | $80.8M | ||
| Q2 25 | $293.2M | $101.4M | ||
| Q1 25 | $321.4M | $108.3M | ||
| Q4 24 | $424.9M | $105.5M | ||
| Q3 24 | $501.9M | $96.0M | ||
| Q2 24 | $541.9M | $105.6M | ||
| Q1 24 | $525.9M | $115.3M |
| Q4 25 | $505.7M | $283.8M | ||
| Q3 25 | $369.0M | $279.6M | ||
| Q2 25 | $420.9M | $289.3M | ||
| Q1 25 | $469.7M | $321.5M | ||
| Q4 24 | $510.6M | $319.6M | ||
| Q3 24 | $552.9M | $314.9M | ||
| Q2 24 | $588.3M | $321.5M | ||
| Q1 24 | $600.6M | $332.0M |
| Q4 25 | $566.7M | $342.0M | ||
| Q3 25 | $424.0M | $342.3M | ||
| Q2 25 | $473.6M | $349.5M | ||
| Q1 25 | $515.7M | $379.0M | ||
| Q4 24 | $560.4M | $384.0M | ||
| Q3 24 | $604.0M | $373.5M | ||
| Q2 24 | $620.1M | $376.7M | ||
| Q1 24 | $629.9M | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | $15.5M |
| Free Cash FlowOCF − Capex | $28.5M | $12.3M |
| FCF MarginFCF / Revenue | 33.5% | 8.2% |
| Capex IntensityCapex / Revenue | 0.1% | 2.1% |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.6M | $15.5M | ||
| Q3 25 | $-46.5M | $12.9M | ||
| Q2 25 | $-43.4M | $14.7M | ||
| Q1 25 | $-47.8M | $11.1M | ||
| Q4 24 | $-134.6M | $20.0M | ||
| Q3 24 | $-29.4M | $9.4M | ||
| Q2 24 | $-30.2M | $18.7M | ||
| Q1 24 | $-29.1M | $7.3M |
| Q4 25 | $28.5M | $12.3M | ||
| Q3 25 | $-46.6M | $7.0M | ||
| Q2 25 | $-43.4M | $9.1M | ||
| Q1 25 | $-48.4M | $10.0M | ||
| Q4 24 | $-138.4M | $16.4M | ||
| Q3 24 | $-31.2M | $2.6M | ||
| Q2 24 | $-30.6M | $10.1M | ||
| Q1 24 | $-29.8M | $5.6M |
| Q4 25 | 33.5% | 8.2% | ||
| Q3 25 | -51765.6% | 5.5% | ||
| Q2 25 | -289620.0% | 6.9% | ||
| Q1 25 | -345635.7% | 7.4% | ||
| Q4 24 | -13837100.0% | 11.2% | ||
| Q3 24 | -1038966.7% | 2.1% | ||
| Q2 24 | -611840.0% | 7.7% | ||
| Q1 24 | -106421.4% | 4.1% |
| Q4 25 | 0.1% | 2.1% | ||
| Q3 25 | 101.1% | 4.6% | ||
| Q2 25 | 440.0% | 4.2% | ||
| Q1 25 | 4507.1% | 0.8% | ||
| Q4 24 | 378600.0% | 2.5% | ||
| Q3 24 | 59266.7% | 5.5% | ||
| Q2 24 | 6980.0% | 6.6% | ||
| Q1 24 | 2535.7% | 1.3% |
| Q4 25 | 1.47× | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
